Investor Presentaiton
11
Investor presentation
Full year 2022
First two human dose initiations with Dicerna in line with
ambition presented at Capital Markets Day 2022
First two phase 1 trials in NASH with siRNA technology initiated
Diabetes care
Obesity care
Trial 1
Target: MARC1
Trial 2
Target: LXR(a)
CVD
32 patients
48 patients
NASH
RBD
RED
Other areas
Trial objectives
The trials are investigating safety, tolerability,
pharmacokinetics and pharmacodynamics of
the respective siRNA-based assets
siRNA: Small interfering RNA; MARC1: Mitochondrial amidoxime reducing component 1; LXR(a): Liver X receptor alpha
Novo Nordisk and Dicerna
•
•
After a productive partnership since 2019, Novo Nordisk
acquired Dicerna pharmaceuticals in 2021 for $3.3 bUSD
Integrated into Novo Nordisk and now operates as a
transformational research unit (TRU) responsible for the
siRNA research technology platform
Setup to preserve the agility and speed of a smaller biotech,
while leveraging the scale and experience of a large
pharmaceutical company
Ambition
•
Generate an average of 3 first human dose projects per year
across therapy areas with the siRNA technology platform
Novo NordiskⓇView entire presentation